4 terminated, 2 recruiting, 1 active not recruiting, 1 enrolling by invitation. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 3 | Terminated 2, Not yet recruiting 1 |
Follow Ryvu Therapeutics SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma RVU120, Everolimus (Afinitor) tablets - Medulloblastoma Recurrent, Medulloblastoma | Phase 1 | Not yet recruiting | Bożenna Dembowska Bagińska | 48 | 2026-09-01 | 2026-10-08 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) MEN1703, Glofitamab - Non-Hodgkin Lymphoma, B-cell | Phase 2 | Recruiting | Ryvu Therapeutics SA | 178 | 2024-12-05 | 2026-09-18 |
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis RVU120, Ruxolitinib - Myelofibrosis | Phase 2 | Terminated | Ryvu Therapeutics SA | 36 | 2024-09-19 | 2026-09-16 |
| RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms RVU120 (SEL120) - Low Risk Myelodysplastic Syndromes | Phase 2 | Active not recruiting | GCP-Service International West GmbH | 41 | 2024-09-10 | 2025-05-22 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Terminated | Ryvu Therapeutics SA | 62 | 2024-01-23 | 2026-09-16 |
| Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML RVU120, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | Ryvu Therapeutics SA | 98 | 2024-01-05 | 2026-09-18 |
| RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors RVU120 - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Ryvu Therapeutics SA | 66 | 2021-08-13 | 2026-09-18 |
| RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome RVU120(SEL120) - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Terminated | Ryvu Therapeutics SA | 51 | 2019-09-04 | 2026-09-18 |
Leukemia, Myeloid, Acute (4) · Recurrence (4) · Neoplasm Metastasis (3) · Myelodysplastic Syndromes (2) · Aggression (1) · Lymphoma, Non-Hodgkin (1) · Medulloblastoma (1) · Primary Myelofibrosis (1)
ruxolitinib (2) · Everolimus (1) · Tablets (1) · glofitamab (1) · venetoclax (1)
Poland (9) · France (5) · Spain (5) · Italy (4) · Germany (1) · United Kingdom (1) · United States (1)
Diez Campelo, Dr. (1) · Uwe Platzbecker, Prof. (1) · Valeria Santini, Prof. (1)
2025 (1)